PLX108-08: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Cancer - Brain
Principal Investigator: Tommy Mikkelsen, MD
The study objectives are to assess the potential for PLX3397 to improve the efficacy of standard of care radiation therapy (RT) + temozolomide in patients with newly diagnosed glioblastoma (GBM).
- Male or female patients =18 years old.
- Histologically confirmed definitive GBM or gliosarcoma by partial or complete surgical resection (i.e. not by biopsy only) within 5 weeks prior to PLX3397 administration (C1D1). Tumor must have a supratentorial component.
- The patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration.
Please contact us for a full list of eligibility criteria.